ZA200307785B - Use of pyridoindolone derivatives for preparing anticancer medicines. - Google Patents
Use of pyridoindolone derivatives for preparing anticancer medicines. Download PDFInfo
- Publication number
- ZA200307785B ZA200307785B ZA200307785A ZA200307785A ZA200307785B ZA 200307785 B ZA200307785 B ZA 200307785B ZA 200307785 A ZA200307785 A ZA 200307785A ZA 200307785 A ZA200307785 A ZA 200307785A ZA 200307785 B ZA200307785 B ZA 200307785B
- Authority
- ZA
- South Africa
- Prior art keywords
- methyl
- group
- hydrogen
- pyrido
- dihydro
- Prior art date
Links
- 239000003814 drug Substances 0.000 title description 5
- 229940079593 drug Drugs 0.000 title description 4
- YNHGMRWHXVMPEN-UHFFFAOYSA-N pyrrolo[2,3-f]quinolin-2-one Chemical class C1=CC=C2C3=NC(=O)C=C3C=CC2=N1 YNHGMRWHXVMPEN-UHFFFAOYSA-N 0.000 title description 3
- 230000001093 anti-cancer Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940126601 medicinal product Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 208000007538 neurilemmoma Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 229940084434 fungoid Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000005001 male reproductive tract Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000005987 myeloid sarcoma Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000007428 synaptic transmission, GABAergic Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0105843A FR2823975B1 (fr) | 2001-04-27 | 2001-04-27 | Nouvelle utilisation de pyridoindolone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200307785B true ZA200307785B (en) | 2004-10-06 |
Family
ID=8862882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200307785A ZA200307785B (en) | 2001-04-27 | 2003-10-06 | Use of pyridoindolone derivatives for preparing anticancer medicines. |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US7524857B2 (de) |
| EP (2) | EP1385512B1 (de) |
| JP (2) | JP2004531538A (de) |
| KR (1) | KR100847413B1 (de) |
| CN (2) | CN1240382C (de) |
| AR (1) | AR034313A1 (de) |
| AT (2) | ATE338548T1 (de) |
| BG (2) | BG108260A (de) |
| BR (1) | BR0209138A (de) |
| CA (2) | CA2444334A1 (de) |
| CY (1) | CY1105813T1 (de) |
| CZ (2) | CZ295224B6 (de) |
| DE (2) | DE60214533T2 (de) |
| DK (2) | DK1385512T3 (de) |
| EA (1) | EA005930B1 (de) |
| EE (2) | EE200300465A (de) |
| ES (2) | ES2271264T3 (de) |
| FR (1) | FR2823975B1 (de) |
| HK (2) | HK1059895A1 (de) |
| HU (2) | HUP0400744A2 (de) |
| IL (4) | IL158312A0 (de) |
| IS (1) | IS2441B (de) |
| MX (1) | MXPA03009639A (de) |
| NO (2) | NO20034787L (de) |
| NZ (1) | NZ528671A (de) |
| PL (2) | PL366910A1 (de) |
| PT (2) | PT1385512E (de) |
| RS (2) | RS50791B (de) |
| RU (1) | RU2292888C9 (de) |
| SK (2) | SK13242003A3 (de) |
| TW (1) | TWI252104B (de) |
| UA (1) | UA74876C2 (de) |
| WO (2) | WO2002087574A2 (de) |
| ZA (1) | ZA200307785B (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2823975B1 (fr) * | 2001-04-27 | 2003-05-30 | Sanofi Synthelabo | Nouvelle utilisation de pyridoindolone |
| FR2846329B1 (fr) * | 2002-10-23 | 2004-12-03 | Sanofi Synthelabo | Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique |
| US7456193B2 (en) | 2002-10-23 | 2008-11-25 | Sanofi-Aventis | Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics |
| FR2869316B1 (fr) * | 2004-04-21 | 2006-06-02 | Sanofi Synthelabo | Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique. |
| FR2892416B1 (fr) | 2005-10-20 | 2008-06-27 | Sanofi Aventis Sa | Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1268772A (en) * | 1968-03-15 | 1972-03-29 | Glaxo Lab Ltd | NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME |
| US4263304A (en) * | 1978-06-05 | 1981-04-21 | Sumitomo Chemical Company, Limited | 7 H-indolo[2,3-c]isoquinolines |
| SU833971A1 (ru) * | 1979-07-10 | 1981-05-30 | Ленинградский Химико-Фармацевтическийинститут | Способ получени 3-фенил-2-оксо- - КАРбОлиНОВ |
| SU833972A1 (ru) | 1979-10-26 | 1981-05-30 | Институт Физико-Органической Химиии Углехимии Ah Украинской Ccp | Имидазо(4,5-с)пиридиний иодиды вКАчЕСТВЕ пРОМЕжуТОчНыХ пРОдуКТОВ дл СиНТЕзА фуНгицидОВ |
| FR2595701B1 (fr) * | 1986-03-17 | 1988-07-01 | Sanofi Sa | Derives du pyrido-indole, leur application a titre de medicaments et les compositions les renfermant |
| US5035252A (en) * | 1990-12-14 | 1991-07-30 | Mondre Steven J | Nicotine-containing dental floss |
| EP0755454B1 (de) * | 1994-04-13 | 2008-02-13 | The Rockefeller University | Aav-vermittelte überbringung von dna in zellen des nervensystems |
| DE19502753A1 (de) * | 1995-01-23 | 1996-07-25 | Schering Ag | Neue 9H-Pyrido[3,4-b]indol-Derivate |
| US6486177B2 (en) * | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
| FR2765581B1 (fr) * | 1997-07-03 | 1999-08-06 | Synthelabo | Derives de 3-aryl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one, leur preparation et leur application en therapeutique |
| FR2765582B1 (fr) * | 1997-07-03 | 1999-08-06 | Synthelabo | Derives de 3-alkyl-1,9-dihydro-2h-pyrido[2,3-b]indol-2-one leur preparation et leur application en therapeutique |
| WO1999051597A1 (en) * | 1998-04-02 | 1999-10-14 | Neurogen Corporation | Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino[2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino[4,5-b]indole derivatives: crf1 specific ligands |
| IT1313592B1 (it) | 1999-08-03 | 2002-09-09 | Novuspharma Spa | Derivati di 1h-pirido 3,4-b indol-1-one. |
| US20020156016A1 (en) * | 2001-03-30 | 2002-10-24 | Gerald Minuk | Control of cell growth by altering cell membrane potentials |
| FR2823975B1 (fr) * | 2001-04-27 | 2003-05-30 | Sanofi Synthelabo | Nouvelle utilisation de pyridoindolone |
| FR2846330B1 (fr) | 2002-10-23 | 2004-12-03 | Sanofi Synthelabo | Derives de pyridoindolone substitues en -3 par groupe heterocyclique, leur preparation et leur application en therapeutique |
| FR2846329B1 (fr) | 2002-10-23 | 2004-12-03 | Sanofi Synthelabo | Derives de pyridoindolone substitues en -3 par un phenyle, leur preparation et leur application en therapeutique |
| US6958347B2 (en) | 2002-12-18 | 2005-10-25 | Pfizer Inc. | Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists |
| FR2869316B1 (fr) * | 2004-04-21 | 2006-06-02 | Sanofi Synthelabo | Derives de pyridoindolone substitues en -6, leur preparation et leur application en therapeutique. |
| FR2892416B1 (fr) | 2005-10-20 | 2008-06-27 | Sanofi Aventis Sa | Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique |
-
2001
- 2001-04-27 FR FR0105843A patent/FR2823975B1/fr not_active Expired - Fee Related
-
2002
- 2002-04-26 WO PCT/FR2002/001449 patent/WO2002087574A2/fr active IP Right Grant
- 2002-04-26 CN CNB028088980A patent/CN1240382C/zh not_active Expired - Fee Related
- 2002-04-26 CZ CZ20032909A patent/CZ295224B6/cs not_active IP Right Cessation
- 2002-04-26 BR BR0209138-0A patent/BR0209138A/pt not_active IP Right Cessation
- 2002-04-26 CN CNA028089596A patent/CN1505511A/zh active Pending
- 2002-04-26 AT AT02735502T patent/ATE338548T1/de not_active IP Right Cessation
- 2002-04-26 KR KR1020037013925A patent/KR100847413B1/ko not_active IP Right Cessation
- 2002-04-26 RU RU2003130376/15A patent/RU2292888C9/ru active
- 2002-04-26 DE DE60214533T patent/DE60214533T2/de not_active Expired - Lifetime
- 2002-04-26 AR ARP020101521A patent/AR034313A1/es unknown
- 2002-04-26 US US10/476,321 patent/US7524857B2/en active Active
- 2002-04-26 SK SK1324-2003A patent/SK13242003A3/sk unknown
- 2002-04-26 SK SK1325-2003A patent/SK13252003A3/sk unknown
- 2002-04-26 IL IL15831202A patent/IL158312A0/xx unknown
- 2002-04-26 DK DK02732841T patent/DK1385512T3/da active
- 2002-04-26 RS YUP-839/03A patent/RS50791B/sr unknown
- 2002-04-26 RS YUP-834/03A patent/RS50790B/sr unknown
- 2002-04-26 JP JP2002584920A patent/JP2004531538A/ja active Pending
- 2002-04-26 WO PCT/FR2002/001450 patent/WO2002087575A1/fr active IP Right Grant
- 2002-04-26 CA CA002444334A patent/CA2444334A1/fr not_active Abandoned
- 2002-04-26 PL PL02366910A patent/PL366910A1/xx unknown
- 2002-04-26 EE EEP200300465A patent/EE200300465A/xx unknown
- 2002-04-26 PT PT02732841T patent/PT1385512E/pt unknown
- 2002-04-26 CA CA002443012A patent/CA2443012C/fr not_active Expired - Fee Related
- 2002-04-26 JP JP2002584919A patent/JP2004528343A/ja active Pending
- 2002-04-26 CZ CZ20032910A patent/CZ299465B6/cs not_active IP Right Cessation
- 2002-04-26 ES ES02735502T patent/ES2271264T3/es not_active Expired - Lifetime
- 2002-04-26 IL IL15826602A patent/IL158266A0/xx unknown
- 2002-04-26 DK DK02735502T patent/DK1385513T3/da active
- 2002-04-26 PT PT02735502T patent/PT1385513E/pt unknown
- 2002-04-26 TW TW091108716A patent/TWI252104B/zh not_active IP Right Cessation
- 2002-04-26 ES ES02732841T patent/ES2254683T3/es not_active Expired - Lifetime
- 2002-04-26 MX MXPA03009639A patent/MXPA03009639A/es active IP Right Grant
- 2002-04-26 EE EEP200300466A patent/EE200300466A/xx unknown
- 2002-04-26 EP EP02732841A patent/EP1385512B1/de not_active Expired - Lifetime
- 2002-04-26 EP EP02735502A patent/EP1385513B1/de not_active Expired - Lifetime
- 2002-04-26 NZ NZ528671A patent/NZ528671A/en unknown
- 2002-04-26 EA EA200301062A patent/EA005930B1/ru not_active IP Right Cessation
- 2002-04-26 AT AT02732841T patent/ATE314070T1/de not_active IP Right Cessation
- 2002-04-26 HU HU0400744A patent/HUP0400744A2/hu unknown
- 2002-04-26 DE DE60208365T patent/DE60208365T2/de not_active Expired - Lifetime
- 2002-04-26 UA UA2003109248A patent/UA74876C2/uk unknown
- 2002-04-26 PL PL02366916A patent/PL366916A1/xx not_active IP Right Cessation
- 2002-04-26 US US10/476,322 patent/US6967203B2/en not_active Expired - Lifetime
- 2002-04-26 HU HU0400745A patent/HUP0400745A2/hu unknown
-
2003
- 2003-10-02 IL IL158266A patent/IL158266A/en not_active IP Right Cessation
- 2003-10-06 ZA ZA200307785A patent/ZA200307785B/en unknown
- 2003-10-08 IL IL158312A patent/IL158312A/en not_active IP Right Cessation
- 2003-10-09 IS IS6984A patent/IS2441B/is unknown
- 2003-10-13 BG BG108260A patent/BG108260A/bg unknown
- 2003-10-13 BG BG108261A patent/BG108261A/bg unknown
- 2003-10-24 NO NO20034787A patent/NO20034787L/no not_active Application Discontinuation
- 2003-10-24 NO NO20034785A patent/NO20034785L/no not_active Application Discontinuation
-
2004
- 2004-04-20 HK HK04102775A patent/HK1059895A1/xx not_active IP Right Cessation
- 2004-05-03 HK HK04103103A patent/HK1060066A1/xx not_active IP Right Cessation
-
2005
- 2005-08-15 US US11/204,275 patent/US7160895B2/en not_active Expired - Lifetime
-
2006
- 2006-11-30 CY CY20061101725T patent/CY1105813T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210100813A1 (en) | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors | |
| US7160895B2 (en) | Use of pyridoindolone derivatives for the preparation of medicinal products | |
| WO2012027392A2 (en) | Antimetastatic compounds | |
| US20090281143A1 (en) | Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity | |
| AU2014245146A1 (en) | Antitumor agent including irinotecan hydrochloride hydrate | |
| US20220218677A1 (en) | Arylquinoziline derivatives as alpha2-adrenoceptor subtype c (alpha-2c) antagonists for the treatment of sleep apnea | |
| CN111821303A (zh) | 沃替西汀及其盐在制备抗肿瘤药物中的应用 | |
| JP2003533474A (ja) | シトレアマイシンの新規の使用 | |
| JPH03502806A (ja) | ガンの処理 |